Proliferative vitreoretinopathy
Abstract
Background: Proliferative vitreoretinopathy (PVR) is a disease characterized by formation of membranes on both surfaces of the retina and vitreous base. PVR is a wound healing response which is inadequate and uncontrolled in the eye. Identifying the risk factors is important for PVR prediction. The distinction between anterior and posterior PVR is essential in predicting the surgery success.
Conclusions: The anatomic and first of all functional success after vitrectomy are relatively poor. To improve the outcome the research has been focused on the use of pharmacological agents to prevent the development of PVR. A combination of 5-fluorouracil and low molecular weight heparin is the only proven effective therapy for PVR prevention.
Downloads
References
Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995; 79: 953–60.
Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994; 14: 417–24.
Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol 1988; 226: 201–5.
Ryan SJ. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 1985; 100: 188–93.
Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991; 111: 8–14.
Lewis H, Aaberg TM. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 1991; 111: 15–9.
Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, et al. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997; 104: 1166–73.
Tolentino FI, Schepens CL, Freeman HM. Massive preretinal retraction. A biomicroscopic study. Arch Ophthalmol 1967; 78: 16–22.
Yoshino Y, Ideta H, Nagasaki H, Uemura A, Kaiser D, Gaskin H. Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy. Retina 1989; 9: 97–100.
Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 1989; 107: 1147–51.
Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 2004; 137: 1105–15.
Lambrou FH, Burke JM, Aaberg TM. Effect of silicone oil on experimental traction retinal detachment. Arch Ophthalmol 1987; 105: 1269–72.
Lewis H, Burke JM, Abrams GW, Aaberg TM. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 1988; 95: 583–91.
Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40: 705–12.
The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121–5.
Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991; 112: 159–65.
Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 1997; 115: 237–41.
Campochiaro PA, Hackett SF, Vinores SA, Freund J, Csaky C, LaRochelle W, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci 1994; 107: 2459–69.
Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 1998; 82: 181–5.
Connor TBJ, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, et al. Correlation of fibrosis and transforming growth factor-beta type 2 in levels in the eye. J Clin Invest 1989; 83: 1661–6.
Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992; 36: 373–84.
Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738–46.
Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-β2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 2000; 41: 1210–6.
El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol 1999; 83: 1296–9.
Hiscott P, Waller HA, Butler MG, Grierson I, Scott DL. Local production of fibronectin by ectopic human retinal cells. Cell Tissue Res 1992; 267: 185–92.
Grisanti S, Heimann K, Wiedemann P. Origin of fibronectin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Br J Ophthalmol 1993; 77: 238–42.
Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 1999; 18: 167–90.
Weller M, Heimann K, Wiedemann P. Mononuclear phagocytes and their growth factors: pacemakers of proliferative vitreoretinopathy. Klin Monatsbl Augenheilkd 1990; 196: 121–7.
Chandler DB, Hida T, Rozakis G, Forbes VS, Machemer R. The lack of an effect of intraocular steroids on irridiated fibroblasts in experimental proliferative vitreoretinopathy. Grafes Arch Clin Exp Ophthalmol 1992; 230: 188.
Chandler DB, Hida T, Sheta S, Proia AD, Machemer R. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Grafes Arch Clin Exp Ophthalmol 1987; 225: 259–65.
Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 90: 810–6.
Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89: 131–6.
Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002; 240: 423–9.
Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis-a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 1982; 219: 268–71.
Raymond MC, Thompson JT. RPE mediated gel contraction. Inhibition by colchicine and stimulation by TGF-beta. Invest Ophthalmol Vis Sci 1990; 31: 1079.
Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral lowdose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg 1989; 20: 268–72.
Verdoorn C, Renardel de Lavalette VW, Dalma-Weizhausz J, Orr GM, Sorgente N, Ryan SJ. Cellular migration, proliferation, and contraction. An in vitro approach to a clinical problem-proliferative vitreoretinopathy. Arch Ophthalmol 1986; 104: 1216–9.
Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 1998; 126: 550–93.
Kon CH, Occleston NL, Foss A, Sheridan C, Aylward GW, Khaw PT. Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracul: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol 1998; 82: 554–60.
Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 1989; 227: 565–8.
Blumenkranz MS, Hernandez E, Ophir A, Norton EW. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmol 1984; 91: 122–30.
Blumenkranz MS, Hartzer MK. Pharmacologic treatment of proliferative vitreoretinopathy: interrelationship with the coagulation cascade. In: Lewis H, Ryan SJ, eds. Medical and surgical retina, advances, controversies and management. St. Louis: Mosby; 1993. p. 172.
Del Vecchio PJ, Bizios R, Holleran LA, Judge TK, Pinto GL. Inhibition of human scleral fibroblast proliferation with heparin. Invest Ophthalmol Vis Sci 1988; 29: 1272–6.
Blumenkranz MS, Hartzer MK, Alvira G. Effect of heparin on cell-mediated contraction and proliferation in human retinal pigment epithelial cells and ocular fibroblasts. In: Heimann K, Wiedemann P, eds. Proliferative vitreoretinopathy. Heidelberg: Kaden-Verlag; 1989. p. 251.
Johnson RN, Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmol 1988; 95: 312–7.
Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol 1991; 109: 405–9.
Asaria RHY, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy. Ophthalmol 2001; 108: 1179–83.
Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RHY, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111: 2240–5.
Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology 2001; 108: 1184–6.
Arroyo MH, Refojo MF, Araiz JJ, Tolentino FI, Cajita VN, Elner VM. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina 1993; 13: 245–50.
Ikuno Y, Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci 2002; 43: 2406–11.
Wong D, Stanga P, Briggs M, Lenfestey P, Lancaster E, Li KK, et al. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol 2004; 88: 186–90.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
